Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 1997

View Archived Issues

Enzon: fiscal 1997 highlights

Algene: Q2 1997 highlights

Safety profile of VRCTC-310 established in rabbits

Boston Life Sciences reports phase III results for Therafectin

Favorable phase II/III data for Targretin in CTCL reported at dermatology congress

Cytel reports encouraging results from Cylexin phase I/II trial

Dyax issued U.S. patent for novel elastase inhibitors

Genetronics receives NCI grant for electroporation research

Quinacrine sterilization reviewed

Efficacy of Viramune triple drug combination reported at ICAAC

Byk Gulden presents new gastric antisecretory agents

Schering AG prepares new rolipram derivatives

Focus on benzoyl guanidines as Na+/H+-exchange inhibitors

Optically active analgesic agent presented by Roche

New polyene antifungal antibiotic developed at Ajinomoto

BioChem Therapeutic discovers new anti-HCMV agents

Development of YM-46303 stopped

North American Vaccine advances with meningitis B vaccine

Dexketoprofen trometamol submitted for mutual EC recognition

Phase II results reported for Neurobloc

Nyotran study results described at ICAAC

Wakunaga develops new oral fluoroquinolones

T-3811: a new des-F(6)-quinolone from Toyama presented at ICAAC

SynPhar selects class C beta-lactamase inhibitor as development candidate

Cor Therapeutics submits NDA amendment for Integrilin to FDA

First registration filing for Unigene's injectable calcitonin product

Five efavirenz studies reported at ICAAC

Triazole antifungal from Uriach heading for clinic

Fortovase compares favorably with Crixivan and Invirase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...